Oligonucleotide News and Research

RSS

New compound can reduce overactivation without impairing the body's immunity response

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

10 Mar 2021

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. Image credit: Shutterstock.com/Billion Photos

From Aptamer Group 5 Mar 2021

New evidence supports the use of antisense oligonucleotides as feasible therapeutic strategy for MDS

Many cognitive neurodevelopmental disorders are a result of too many or too few copies of certain genes or chromosomes.

5 Mar 2021

Study identifies potential therapeutic target for non-alcoholic fatty liver disease

An international team of researchers has identified the CNNM4 protein as a key regulator of magnesium in the liver and potential therapeutic target for non-alcoholic fatty liver disease, according to a study published in the Journal of Hepatology.

4 Mar 2021

Researchers develop a genetic patch to prevent hereditary deafness

They can hear well up to about forty years old, but then suddenly deafness strikes people with DFNA9. The cells of the inner ear can no longer reverse the damage caused by a genetic defect in their DNA.

2 Mar 2021

A new hub established for development of oligonucleotide drugs

In recent years, techniques have been developed to treat diseases with what are known as oligonucleotide drugs, based on short DNA or RNA molecules.

1 Mar 2021

FDA approval provides targeted treatment option for patients with rare DMD mutation

Today, the U.S. Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping (Exons are pieces of DNA that provide information for making proteins in a person's genome).

25 Feb 2021

mRNA Therapeutics – Analytical and Bioanalytical Characterization

NewsMed interviews Anette Bak from AstraZeneca about her research on developments in mRNA therapeutics that she will present at Pittcon 2021.

From Pittcon 23 Feb 2021

Taking Advantage of Measuring Molecular Collisional Cross-Sections in Pharma

News-Medical talks to Mike Greig, Director of Pharma at Bruker, about why measuring collisional cross-sections is beneficial to developing new drugs.

From Bruker Daltonics 10 Feb 2021

Novel immunotherapy approach to revert the main hallmarks of cat allergy

Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully modulating the immune system's allergic response to the main cat allergen Fel d 1, thereby inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy.

5 Feb 2021

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

20 Jan 2021

Researchers develop ultra-small nanomedicines to target intractable cancers

Ultra-small nanomedicines of approximately 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and nucleic acid drugs, such as siRNA and antisense drugs.

19 Jan 2021

Replacing the RNA strand with DNA may enhance efficacy of ASO-based drugs

Antisense oligonucleotides (ASO) hold great promise for pharmacotherapy. Now, researchers at Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, advancing their earlier work on a heteroduplex oligonucleotide (HDO) model, have demonstrated augmentation of ASO-based drugs by replacing the RNA strand with DNA.

5 Jan 2021

A paper-based sensor for detecting COVID-19

News-Medical talks to Dipanjan Pan about the development of a paper-based electrochemical sensor that can detect COVID-19 in less than five minutes.

5 Jan 2021

FDA takes first steps in bringing clarity to emerging area of individualized drug development

Advances in scientific knowledge and drug development technology have provided an opportunity for new approaches to drug development, including the development of drugs for the treatment of rare diseases.

4 Jan 2021

Gene-regulating snippet of RNA may contribute to breast cancer metastasis

Cold Spring Harbor Laboratory (CSHL) scientists have discovered a gene-regulating snippet of RNA that may contribute to the spread of many breast cancers.

22 Dec 2020

Paper-based electrochemical sensor can enable rapid detection of SARS-CoV-2

As the COVID-19 pandemic continues to spread across the world, testing remains a key strategy for tracking and containing the virus.

7 Dec 2020

Adding exercise to genetic treatment reverses fatigue in mice with common myotonic dystrophy

Adding exercise to a genetic treatment for myotonic dystrophy type 1 (DM1) was more effective at reversing fatigue than administering the treatment alone in a study using a mouse model of the disease.

30 Nov 2020

SARS-CoV-2 RNA genome structure reveals potential targets for development of drugs

The SARS-CoV-2 coronavirus RNA genome structure was studied in detail by researchers from the University of Groningen, the International Institute of Molecular and Cell Biology in Warsaw, and Leiden University.

10 Nov 2020

RNA-binding proteins may suppress antiviral defenses against SARS-CoV-2

Conducted by researchers in South Korea at the Institute for Basic Science and the International Vaccine Institute, a new study published on the preprint server bioRxiv in November 2020 describes the many host proteins that bind with the ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulate the replication of the virus.

4 Nov 2020